Research Funded

Dissecting the contribution of germline genetics to pediatric sarcoma pathogenesis

Riaz Gillani, MD, Dana-Farber Cancer Institute
Recipient of the: $50,000 Jay Vernon Jackson Memorial Research Award

Abstract: Amongst pediatric cancers, bone and soft tissue sarcomas are often associated with the poorest prognoses and most limited effective treatment options. Understanding the genetics that predispose to the development of childh... Read More

Endoglin CAR T cells for Immunotherapy of Ewing Sarcoma

Sujith Kurian Joseph, PhD, Baylor College of Medicine
Recipient of the: $50,000 Pittsburgh Cure Sarcoma/Giving Tuesday Research Award

Abstract: Ewing sarcoma is the second common bone cancer in children and young adults. It is an aggressive type of cancer that spreads rapidly to other organs in the body. Ewing sarcoma that recurs or that has spread to other parts ... Read More

Multi-faceted immunostimulatory therapy for Ewing Sarcoma (MITES)

Margaret Chou, PhD, Children's Hospital of Philadelphia
Recipient of the: $50,000 The Philadelphia Flyers Community Research Award Honoring Oskar Lindblom

Abstract: Ewing sarcoma (ES) is the second most pediatric common bone cancer (1,2). While patients with localized disease have a five-year survival rate of ~75%, this plummets to 20% for metastatic and recurrent disease. Immunothera... Read More

Development of T cell receptors targeting the common cancer antigen PRAME in pediatric malignancies

David Milewski, PhD, National Institutes of Health, National Cancer Institute
Recipient of the: $50,000 Spring for Sarcoma/Zach Cohen Memorial Research Award

Abstract: Antigen presentation is a universal process in which proteins in a cell are degraded into small fragments (peptides) and displayed on the cell surface for interrogation by the immune system. If a peptide is derived from an... Read More

Mechanisms of Arginine Starvation Induced Cell Death

Brian Van Tine, PhD, Washington University in St. Louis, MO
Recipient of the: $50,000 St. Louis Cure Sarcoma 6k Research Award

Abstract: PEGylated Arginine Deiminase (ADI-PEG20) is a therapeutic that degrades extracellular arginine.  In tumors like sarcoma that cannot make their own arginine due to a urea cycle defect, this agent put tumors into a starvati... Read More

Hippo pathway targeting in uterine leiomyosarcoma

Annalisa Astolfi, PhD, University of Ferrara
Recipient of the: $50,000 Dr. Richard and Valerie Aronsohn Memorial Research Award

Abstract: Leiomyosarcoma is the most common type of uterine sarcoma (uLMS), with an annual incidence of slightly less than two women per 100,000, characterized by a very poor response to standard therapies and an aggressive clinical... Read More

Genomewide therapeutic target screens in novel preclinical models of liposarcoma

Wantong Yao, PhD, The University of Texas MD Anderson Cancer Center
Recipient of the: $50,000 Jay Vernon Jackson Memorial Research Award

Abstract:  Liposarcoma is one of the most common soft-tissue sarcomas, with well-differentiated/dedifferentiated liposarcoma subtype forming the majority of cases. Although recurrences are frequent, surgery remains the mainstay of ... Read More

Enhanced NK cell Immunotherapy for Treatment of Chemotherapy Refractory Sarcoma

Daniel Vallera, PhD, University of Minnesota – Twin Cities
Recipient of the: $50,000 Dr. Richard and Valerie Aronsohn Memorial Research Award

Abstract: Radiation therapy is a crucial treatment modality required to control soft tissue and advanced bone sarcomas. Despite technological advancements used to treat radioresistant sarcomas, local recurrence and metastasis contin... Read More

MCL-1 inhibition unmasks BCL-2 addiction in synovial sarcoma

Anthony Faber, PhD, Virginia Commonwealth University
Recipient of the: $50,000 Zach Cohen Memorial Research Award

Abstract: Metastatic Synovial Sarcoma (mSS) is frequently diagnosed in teenagers and young adults and continues to be treated with polychemotherapy with variable success. The SS18-SSX gene fusion is pathogenomic for the disease, and... Read More

Identification of novel drug targets and predictors of clinical outcomes in desmoplastic small round cell tumors using next-generation sequencing

Madelyn Espinosa-Cotton, PhD, Memorial Sloan-Kettering Cancer Center
Recipient of the: $50,000 Zach Cohen Memorial Research Award

Abstract: Desmoplastic small round cell tumor (DSRCT) is a rare, highly-aggressive soft-tissue sarcoma with an overall five-year survival rate of less than 30%. Next generation sequencing (NGS) has given cancer researchers unprecede... Read More

Unraveling the tumor immune microenvironment of angiosarcomas

Yvonne Versleijen-Jonkers, PhD, Radboud University Nijmegen Medical Center
Recipient of the: $50,000 Catherine Malatesta Memorial Research Award

Abstract: Is immune checkpoint inhibition the solution for angiosarcoma patients? Genetic and immune profiles of angiosarcoma subtypes will lead to novel insights for the design of individualized immune checkpoint-based therapy for ... Read More

Identifying mechanisms of osteosarcoma chemoresistance that arise from the lung metastatic niche

Ryan Roberts, MD, PhD, The Research Institute at Nationwide Children’s Hospital
Recipient of the: $50,000 Pittsburgh Cure Sarcoma Research Award

Abstract: A therapy preventing the emergence of lung metastasis in adolescents with osteosarcoma could save more than 70% of the lives currently lost to this disease. This would represent the most significant improvement in outcome ... Read More

Imaging response to CD47 mAb immunotherapy in pediatric patients with osteosarcoma

Heike Daldrup-Link, MD, PhD, Stanford University
Recipient of the: $50,000 Race to Cure Sarcoma Research Award

Abstract: Children with metastatic bone cancer have a poor prognosis, with an overall survival rate of less than 30%. Stanford investigators developed a new drug, monoclonal antibodies against the cancer cell marker CD47 (CD mAb), w... Read More

The Role of Pseudogenes as Regulators of the IGF2BP2/IGF1R/RAS Axis in Rhabdomyosarcoma: Functional Characterization in Myogenesis and Implications for Anticancer Therapy

Sonia Guil, PhD, Josep Carreras Leukaemia Research Institute
Recipient of the: $50,000 Race to Cure Sarcoma Research Award

Abstract: In the study of cellular mechanisms that are out of control in cancer, noncoding RNAs(ncRNAs) are becoming increasingly important: these are transcripts that do not code for proteins, but which frequently play regulatory r... Read More

Phase I-II trial of sunitinib plus nivolumab after standard treatment in advanced soft tissue and bone sarcomas

Javier Martin-Broto, MD, PhD, Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla
Recipient of the: $50,000 Race to Cure Sarcoma Research Award

Abstract: Sarcomas are rare, life-threatening, malignant tumors affecting soft, visceral, and bone tissues. Due to their high heterogeneity (more than 60 subtypes), many sarcomas lack effective therapies. Incidence is 50-60 new case... Read More

Immunomodulation of Ewing sarcoma to enhance allogenic NK cell therapy

Masanori Hayashi, MD, University of Colorado Denver
Recipient of the: $50,000 Sarcoma Foundation of America Research Award

Abstract: While the introduction of the combination of intensive chemotherapy and multi-modal While the use of chemotherapy, surgery and irradiation have improved outcomes in Ewing sarcoma (ES), such about 70% of patients are cure, ... Read More

Dissecting DNA damage and repair pathways in leiomyosarcomas: Improving therapy by understanding biology

Annette Duensing, MD, University of Pittsburgh Cancer Institute
Recipient of the: $50,000 Dr. Richard and Valerie Aronsohn Memorial Research Award

Abstract: Leiomyosarcomas (LMS) are aggressive tumors of the smooth muscle with no available effective treatments and a 2-year survival rate of 20%. They represent up to 25% of all soft tissue sarcomas (STS) and are the most common ... Read More